Rapport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	78.06	52.65	56.81	70.17
Short-Term Investments	398.73	437.89	248.48	77.31
Cash & Short-Term Investments	476.78	490.54	305.28	147.48
Cash Growth	67.07%	60.69%	107.00%	-
Accounts Receivable	0.06	-	-	-
Other Current Assets	7.86	8.02	4.52	3.39
Total Current Assets	484.7	498.56	309.8	150.87
Net Property, Plant & Equipment	11.85	12.89	4.97	4
Other Long-Term Assets	1.06	0.99	0.16	0.55
Total Assets	497.6	512.43	314.93	155.42
Accounts Payable	6.56	4.19	1.95	2.5
Accrued Expenses	8.72	12.1	6.08	5.63
Current Portion of Leases	2.62	2.76	0.74	0.67
Total Current Liabilities	17.9	19.05	8.77	8.8
Long-Term Leases	8.19	8.73	0.74	1.48
Other Long-Term Liabilities	-	-	-	4.2
Total Long-Term Liabilities	8.19	8.73	0.74	5.68
Total Liabilities	26.09	27.78	9.51	14.48
Common Stock	0.05	0.05	0.04	0
Additional Paid-in Capital	727.05	719.29	429.66	19.8
Accumulated Other Comprehensive Income	-0.51	0.55	-0.52	0
Retained Earnings	-255.09	-235.23	-123.75	-45.44
Total Common Shareholders' Equity	471.51	484.65	305.43	-25.63
Minority Interest	-	-	-	166.58
Shareholders' Equity	471.51	484.65	305.43	140.94
Total Liabilities & Equity	497.6	512.43	314.93	155.42
Total Debt	10.8	11.48	1.48	2.15
Net Cash (Debt)	465.98	479.06	303.8	145.33
Net Cash Growth	-2.73%	57.69%	109.04%	-
Net Cash Per Share	11.12	12.30	14.65	96.52
Book Value	471.51	484.65	305.43	-25.63
Book Value Per Share	11.25	12.45	14.73	-17.02
Tangible Book Value	471.51	484.65	305.43	-25.63
Tangible Book Value Per Share	11.25	12.45	14.73	-17.02

SEC Filings: 10-K · 10-Q